Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
The company has three FDA-approved products:Alliance Global Partners initiated coverage on Scilex Holding Company (NASDAQ:SCLX), a company focused on non-opioid pain treatment solutions.
全球合作伙伴公司初始对Scilex Holding Company (NASDAQ:SCLX) 进行了覆盖，这是一家专注于非阿片类疼痛治疗解决方案的公司。
On Wednesday, Scilex announced that its board of directors authorized management to explore strategic options, including a potential spinoff or dividend distribution the common stock
周三，Scilex宣布其董事会授权管理层探讨战略选择，包括潜在的剥离或派息普通股。
The board is also considering a public listing of Scilex Pharma's securities on exchanges outside the U.S., such as in Hong Kong, or other strategic transactions.
董事会同时考虑将Scilex Pharma证券在美国以外的交易所进行公开上市，比如在香港，或者其他战略性交易。
The company has three FDA-approved products:
该公司有三个FDA批准的产品：
- Lead drug product ZTlido, a 1.8% lidocaine topical product targeting neuropathic pain associated with postherpetic neuralgia or shingles pain.
- Elyxyb (celecoxib oral solution) for the acute treatment of migraine.
- Gloperba (colchicine USP) for painful gout flares in adults.
- 主导药物产品ZTlido，一种目标是神经病理性疼痛（如带状疱疹后神经痛或带状疱疹疼痛）的1.8%利多卡因局部产品。
- Elyxyb（依来昔布口服溶液），用于急性偏头痛治疗。
- Gloperba（秋水仙碱USP），用于治疗成人痛风发作。
Scilex's Phase 3 candidate, SEMDEXA (SP-102), a non-opioid injectable corticosteroid gel designed to treat lumbosacral radicular pain, commonly known as sciatica.
Scilex的第三阶段候选药物SEMDXA（SP-102），一种非阿片类可注射的皮质类固醇凝胶，旨在治疗腰骶神经根痛，俗称坐骨神经痛。
The current treatment involves off-label use of epidural steroid injections, administered more than 12 million times a year.
目前的治疗方案涉及使用硬膜外肾上腺皮质类固醇注射剂的剂量，每年超过1200万次。
If approved, SEMDEXA can become the standard treatment for sciatica. At its peak, it could reach blockbuster status and generate over $1 billion in annual sales.
如果获批，SEMDEXA可以成为坐骨神经痛的标准治疗方法。在巅峰时期，它有可能达到暴利地位，并创造超过10亿美元的年销售额。
Scilex is set to begin a Phase 3 safety trial for SEMDEXA in the fourth quarter of 2024. A possible FDA marketing application submission is planned for 2026. If approved, the product could launch in 2027.
Scilex计划在2024年第四季度开始进行SEMDEXA的第3阶段安全试验。可能会在2026年提交FDA的营销申请。如果获批，该产品可能会在2027年上市。
The analyst anticipates that SEMDEXA, once on the market, could generate $1.2 billion in sales by 2030.
分析师预计，一旦SEMDEXA上市，到2030年其销售额可能达到12亿美元。
Alliance initiates Scilex Holding with a Buy rating and a price target of $14.
Alliance以买入评级和14美元的目标价启动Scilex Holding。
In July, Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
7月，Scilex Holding Company的全资子公司Semnur Pharmaceuticals Inc.与特殊目的收购公司Denali Capital Acquisition Corp.（纳斯达克：DECA）签署了一份拟议业务合并的意向书。
Price Action: Scilex stock is up 6.5% at 86 cents at last check Wednesday.
股价走势：上周三最后一次交易时，Scilex股价上涨6.5%，报0.86美元。
- Citigroup Remains A Compelling Investment Opportunity: Analysts Take On Q3 Performance
- 花旗集团仍然是一个引人注目的投资机会：分析师对第三季度表现的看法
